Edwards Lifesciences edges higher, P/E near 51 as growth slows
Edwards Lifesciences shares rose 1.67% to $90.56 on Monday, recovering within the upper half of a 52-week range that spans $74.43 to $96.29. The stock carries a trailing P/E of 50.61, elevated relative to earnings per share of $1.73. Revenue grew 14.5% year over year, but EPS collapsed 75.2%, reflecting a sharp margin squeeze. Net margin stands at 15.4%. The Alpha Score of 41 is driven by momentum at 68.8 and quality at 51.6, while value scores just 11.7. The market is pricing in a recovery in profitability that has not yet materialized in reported results. Investors will watch next quarter's earnings for evidence that cost pressures are easing and whether the top-line growth rate can sustain the current multiple.